Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Growth Potential: How Will Market Size Change Through 2030?
The market for viral vector contract development and manufacturing organizations (CDMOs) has experienced swift expansion in recent years. Projected to rise from $1.47 billion in 2025 to $1.7 billion in 2026, this growth reflects a compound annual rate (CAGR) of 15.6%. Several factors drove this historical period’s expansion, including a growing clinical pipeline for gene therapies, early-stage outsourcing of viral vector production, the broadening of academic research partnerships, the constrained internal manufacturing capacities of biotechnology companies, and a rising number of regulatory approvals granted for viral vectors.
The viral vector contract development and manufacturing organization (CDMO) market is anticipated to experience substantial expansion over the coming years. By 2030, its value is projected to reach $3.01 billion, reflecting a compound annual growth rate (CAGR) of 15.3%. This projected growth during the forecast period is driven by several factors, including the increased commercialization of gene and cell therapies, heightened investment in specialized viral vector facilities, a rising need for scalable manufacturing platforms, the broadening of global CDMO collaborations, and progress in high-yield vector production technologies. Key trends anticipated in the forecast period encompass the scaling up of capacity for large-scale viral vector production, a growing preference for single-use manufacturing technologies, an increased need for comprehensive end-to-end CDMO services, a stronger emphasis on cGMP-compliant facilities meeting regulatory standards, and the deeper incorporation of advanced analytics into vector manufacturing processes.
Download A Free Sample Report For Comprehensive Market Insights:
Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Demand Drivers: What Is Fueling Industry Growth?
The anticipated expansion of the viral vector contract development and manufacturing organization (CDMO) market is being driven by increasing financial commitments to gene therapy research. This area of study involves investigating methods for modifying or regulating genes within human cells to correct inherited disorders or fight a variety of diseases. The growing volume of investment in gene therapy research stems from its capacity to deliver durable or permanent cures for genetic conditions that were previously untreatable, which has attracted considerable interest from healthcare innovators and investors alike. Viral vector CDMOs play a crucial role in supporting gene therapy research by providing specialized expertise and state-of-the-art manufacturing infrastructure to produce high-quality viral vectors—essential tools for the secure and effective delivery of therapeutic genes. As an example, in July 2025, the Office for Life Sciences, a UK government agency, announced a government pledge of up to $800 million (£600 million) to create one of the world’s most sophisticated, secure, and AI-compatible health data platforms. This platform will integrate genomic, diagnostic, and clinical data at a population level, transforming NHS and broader healthcare information into a central hub for global research trials and AI investment. Consequently, the rising investment in gene therapy research is fueling the growth of the viral vector contract development and manufacturing organization (CDMO) market.
Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Segment Landscape: Which Areas Lead Market Development?
The viral vector contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Service Type: Process Development, Manufacturing, Analytical Testing, Fill-Finish, Other Service Types
2) By Vector Type: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Vector Types
3) By Workflow: Upstream Manufacturing, Downstream Manufacturing
4) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Process Development: Upstream Process Development, Downstream Process Development, Analytical Development, Process Characterization
2) By Manufacturing: Clinical Manufacturing, Commercial Manufacturing, cGMP Manufacturing, Cell Bank Production, Fill-Finish Services
3) By Analytical Testing: Release Testing, Stability Testing, Bioassays, Characterization Studies, Regulatory Compliance Testing
4) By Fill-Finish: Aseptic Filling, Lyophilization, Final Packaging, Cold Chain Management, Labeling And Serialization
5) By Other Service Types: Regulatory Support, Supply Chain Management, Technology Transfer, Clinical Trial Support, Cold Chain Logistics
Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Innovation Trends: Which Developments Are Transforming The Industry?
Key industry players in the viral vector contract development and manufacturing organization (CDMO) market are concentrating on creating sophisticated offerings like AAV manufacturing solutions to enable scalable and reliable production. These AAV manufacturing solutions encompass methods and systems developed to generate safe and effective adeno-associated virus vectors for gene therapy efficiently. For example, in August 2025, ProBio, a U.S.-based CDMO, introduced cGMP Adeno-Associated Virus (AAV) manufacturing services at its state-of-the-art 128,000 sq. ft. facility in Hopewell, New Jersey. This growth is intended to address the rising demand for premium viral vector production, underscoring ProBio’s commitment to advancing innovative gene therapies. The Hopewell site is specifically designed to deliver comprehensive AAV manufacturing solutions that align with global regulatory and quality benchmarks. ProBio’s expanded capabilities now cover fully integrated services, including GMP plasmid DNA production, AAV vector manufacturing, and final drug product formulation with aseptic fill/finish, all consolidated in one U.S. location. Such integration enhances coordination, minimizes process transitions, and accelerates timelines throughout the drug development cycle.
Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Industry Leaders And Market Competition
Major companies operating in the viral vector contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Genesail Biotech Co. Ltd., CEVEC Pharmaceuticals, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc.
Access The Complete Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Report:
Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the viral vector contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model